false 0001649989 0001649989 2024-12-03 2024-12-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 3, 2024

 

 

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware 001-37759 38-3982704
(State or other jurisdiction
of incorporation) 		(Commission File Number) (IRS Employer Identification No.)

 

111 S. Wood Avenue, Unit #100

Iselin, New Jersey

 08830
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (609) 619-3990

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange 
on Which Registered
Common Stock   OTLK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Departure of Chief Executive Officer

 

On December 3, 2024, C. Russell Trenary III stepped down as the President and Chief Executive Officer of Outlook Therapeutics, Inc. (the “Company”) and as a member of the Company’s Board of Directors (the “Board”), effective immediately (the “Effective Date”). The Board has resolved to reduce its size to nine directors immediately upon Mr. Trenary’s resignation.

 

Mr. Trenary’s departure constitutes a termination of employment without “cause” for purposes of any employment, equity compensation or benefit agreement, plan or arrangement of the Company and its subsidiaries to which Mr. Trenary is a party or otherwise participates, including that certain executive employment agreement, dated as of July 6, 2021, by and between Mr. Trenary and the Company (the “Employment Agreement”). Accordingly, subject to Mr. Trenary’s execution and non-revocation of a separation agreement containing a release of claims against the Company, Mr. Trenary will receive severance benefits consistent with the Employment Agreement for a termination of employment without “cause.” A description of Mr. Trenary’s severance benefits is set forth in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on June 26, 2024, and is incorporated by reference herein.

 

Appointment of Interim Chief Executive Officer

 

On December 3, 2024, Lawrence A. Kenyon, 59, the Company’s Chief Financial Officer, was appointed Interim Chief Executive Officer of the Company, effective as of the Effective Date, to serve while the Board conducts a formal search process to identify and appoint a permanent Chief Executive Officer. Mr. Kenyon’s biographical information is set forth in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on February 8, 2024, and is incorporated by reference herein. There are no arrangements or understandings between Mr. Kenyon and any other persons pursuant to which he was appointed as Interim Chief Executive Officer. There are no family relationships between Mr. Kenyon and any of the Company’s other directors or executive officers, and Mr. Kenyon is not a party to any transaction, or any proposed transaction, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Outlook Therapeutics, Inc.
   
Date: December 4, 2024 By: /s/ Lawrence A. Kenyon
    Lawrence A. Kenyon
    Interim Chief Executive Officer and Chief Financial Officer

 

 

 

v3.24.3
Cover
Dec. 03, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 03, 2024
Entity File Number 001-37759
Entity Registrant Name Outlook Therapeutics, Inc.
Entity Central Index Key 0001649989
Entity Tax Identification Number 38-3982704
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 111 S. Wood Avenue
Entity Address, Address Line Two Unit #100
Entity Address, City or Town Iselin
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08830
City Area Code 609
Local Phone Number 619-3990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OTLK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Outlook Therapeutics Charts.
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Outlook Therapeutics Charts.